loading page

Prognostic value of systematic lymphadenectomy in patients with ovarian cancer: A systematic review and meta-analysis
  • +10
  • AlBatool AlMahdy,
  • Gena Elassall,
  • Ahmed Abdelbadee,
  • Ahmed Yassien Abd-Elkariem,
  • Fatma Atef,
  • Islam Ahmed,
  • Esraa Sayed,
  • Mohamed Ashraf,
  • Ahmed Ali,
  • Esraa Ragab,
  • Hossam Aldein Abd Elazeem,
  • Mahmoud Saad,
  • Sherif Shazly
AlBatool AlMahdy

Corresponding Author:albatool.almahdy.mogge@gmail.com

Author Profile
Gena Elassall
Author Profile
Ahmed Abdelbadee
Assiut University
Author Profile
Ahmed Yassien Abd-Elkariem
Assiut University
Author Profile
Fatma Atef
Author Profile
Islam Ahmed
Author Profile
Esraa Sayed
Author Profile
Mohamed Ashraf
Assiut University Faculty of Medicine
Author Profile
Esraa Ragab
Author Profile
Hossam Aldein Abd Elazeem
Author Profile
Mahmoud Saad
Author Profile
Sherif Shazly
Author Profile


Background: Standard management of ovarian cancer is surgical debulking and adjuvant chemotherapy. The role of systematic lymphadenectomy, as a part of debulking, has been controversial. Objective: To assess prognostic value of systematic lymphadenectomy in women with ovarian cancer based on stage, control group and type of chemotherapy Search strategy: A literature search was conducted on SCOPUS, PUBMED, COCHRANE, MEDLINE, and WEB OF SCIENCE databases. Selection criteria: All comparative studies that assess outcomes of systematic lymphadenectomy in patients with ovarian cancer were eligible. Data Collection and Analysis: overall survival was analyzed by pooling log hazard ratio (HR) and standard error of multivariable Cox regression models. MOGGE Meta-analysis Matrix is a novel illustration tool that was used to demonstrate multiple subgroup analyses of included studies. Main results: Twenty-two studies were eligible. Systematic lymphadenectomy was associated with better overall survival, that was close to significance, compared to control group (HR 0.93, 95%CI 0.86-1.00). Among women treated with adjuvant chemotherapy, overall survival improved in women with stage IIB-IV who underwent systematic lymphadenectomy (HR 0.91, 95%CI 0.84-0.99) and was most significant among patients with III to IV (HR 0.85, 95%CI 0.73-0.99). Systematic lymphadenectomy did not improve survival in women who received neoadjuvant chemotherapy (HR 0.97, 95%CI 0.73-1.29). Systematic lymphadenectomy was associated with improved progress-free survival compared to control group (HR 0.88, 95%CI 0.79-0.99). Conclusion: Data from clinical trials do not support role of systematic lymphadenectomy in advanced ovarian cancer. However, further studies may be warranted to assess substage-specific survival outcomes in women with advanced stages.
Dec 2021Published in European Journal of Obstetrics & Gynecology and Reproductive Biology volume 267 on pages 179-185. 10.1016/j.ejogrb.2021.02.008